Alerta

MILK DERIVED EXOSOMES AND USES THEREOF

Resumen de: US20260014085A1

Described herein are milk exosomes and uses thereof. In some embodiments, the milk exosomes are capable of targeting an injury site or a cancer cell or population thereof. The milk exosomes can contain an exogenous cargo. Described herein are formulations containing the milk exosomes, and optionally, a targeting agent, such as IgG or stimulation of ATP concentration, and/or ADP. Also described herein are methods of delivering a cargo to a target.

IONIZABLE LIPID CONTAINING BIODEGRADABLE ESTER BOND AND LIPID NANOPARTICLES COMPRISING SAME

Resumen de: US20260014075A1

The present disclosure relates to a novel ionizable lipid containing a biodegradable ester bond. The ionizable lipid containing an ester bond, according to the present disclosure, stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, in delivering nucleic acids, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.

COMPOSITIONS AND METHODS INVOLVING TRANSFORMING EXTRACELLULAR VESICLES

Resumen de: US20260014078A1

An extracellular vesicle includes an exogenous therapeutic component. The exogenous therapeutic component can include a therapeutic polypeptide, a polynucleotide that encodes a therapeutic polypeptide, a therapeutic nucleic acid, or a therapeutic agent. In some embodiments, the extracellular vesicle includes an exosome or purified exosome product (PEP).

NOVEL METHODS TO ENHANCE GENE DELIVERY

Resumen de: US20260014077A1

Disclosed are nanoparticle preparations including a nucleic acid agent, a nucleic acid carrier, a metal salt, a polyethylene glycol (PEG)-lipid, a phospholipid, and a cholesterol or its derivative. Also provided are preparation methods and methods for treating or preventing a condition in a subject using such a nanoparticle preparation.

SURFACE PEGYLATED SOLID LIPID NANOCARRIER DUALLY LOADED WITH ATAZANAVIR AND ELVITEGRAVIR FOR COMBINATION ANTIRETROVIRAL THERAPY

Resumen de: US20260014076A1

A preparation of PEGylated solid lipid core nanocarriers (SLN) is loaded with at least one drug for delivery to a subject. SLNs having a small size, neutral charge, and high drug encapsulation efficiency are formed. PEGylation improves SLN permeability without hindering cellular uptake, particularly permeability of nasal mucous for intranasal delivery. PEGylated SLNs are suitable for intranasal, inhaled, oral or injected drug delivery. Exemplary formulations include a combined antiretroviral therapy (cART) designed to cross the blood-brain barrier and treat neuroAIDS.

CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORS

Resumen de: WO2026015458A1

The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising an antigen-recognizing receptor (e.g., a HIT receptor) and an inhibitory polynucleotide. These cells have improved activity and/or efficiency.

CATIONIC LIPIDS, LIPID NANOPARTICLES COMPRISING THE SAME AND METHODS OF DELIVERING NUCLEIC ACIDS

Resumen de: WO2026015822A1

A cationic lipid, a lipid nanoparticle containing the cationic lipid, and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject.

CATIONIC LIPIDS, LIPID NANOPARTICLES COMPRISING THE SAME AND METHODS OF DELIVERING NUCLEIC ACIDS

Resumen de: WO2026015831A1

A cationic lipid, a lipid nanoparticle containing the cationic lipid, and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject.

DNA ORIGAMI NANCOMPLEXES FOR SELECTIVE DELIVERY OF IMAGING AND THERAPEUTIC AGENTS TO KRAS-MUTANT PANCREATIC CANCER CELLS

Resumen de: WO2026015812A1

Labelled DNA Origami for selective imaging of KRAS-mutant pancreatic cancer cells in a desmoplastic pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) are disclosed, as well as DNA Origami nanocomplexes for targeted delivery of a therapeutic payload to KRAS-mutant pancreatic cancer cells in a subject.

HYBRID NANOMATERIALS FOR ASSISTED CORAL RECRUITMENT AND REEF REHABILITATION

Resumen de: WO2026015741A1

A hybrid nanomaterial for coral recruitment includes silica nanoparticles that encapsulate exometabolites and a hydrogel matrix comprising a photopolymerizable material. The silica nanoparticles and the hydrogel matrix are combined to form a nanoink coating for crosslinking on a substrate that can be retained in a reef framework in natural seawater. The hybrid nanomaterial mimics the biochemical attractants, i.e., the "smell," of healthy reefs, thereby enhancing coral recruitment.

NOVEL METHODS TO ENHANCE GENE DELIVERY

Resumen de: WO2026015717A1

Disclosed are nanoparticle preparations including a nucleic acid agent, a nucleic acid carrier, a metal salt, a polyethylene glycol (PEG)-lipid, a phospholipid, and a cholesterol or its derivative. Also provided are preparation methods and methods for treating or preventing a condition in a subject using such a nanoparticle preparation.

NON-VIRAL VECTOR-MEDIATED LARGE-FRAGMENT DNA SITE-DIRECTED KNOCK-IN SYSTEM

Resumen de: WO2026012450A1

Provided are a method for introducing a target nucleic acid sequence into a primary cell, and a nucleic acid-lipid nanoparticle composition encapsulating a linear DNA. The target nucleic acid sequence is inserted into the genome of the primary cell and/or expressed in the primary cell. The method comprises contacting the primary cell with the nucleic acid-lipid nanoparticle composition encapsulating the linear DNA.

DRUG, METHOD, AND USE FOR TREATING DISEASES CAUSED BY AUTOANTIBODY PRODUCTION RESULTING FROM EXCESSIVE PROLIFERATION OF B CELLS

Resumen de: WO2026012294A1

Provided are a drug, a method, and use for treating diseases caused by autoantibody production resulting from excessive proliferation of B cells. The drug for treating diseases caused by autoantibody production resulting from excessive proliferation of B cells comprises: an mRNA encoding a chimeric antigen receptor molecule and a T cell targeting lipid nanoparticle. The drug can produce a chimeric antigen receptor T cell in vivo. The lipid nanoparticle comprises: a cationic lipid, a phospholipid, cholesterol, a PEG lipid, and a targeting molecule. The targeting molecule mediates T cell targeting. The lipid nanoparticle encapsulating the mRNA of the chimeric antigen receptor molecule (mRNA-LNP) is used to deliver the mRNA into a T cell in vivo to produce the chimeric antigen receptor T cell, and pathological autoreactive B cells are eliminated to achieve the treatment of diseases caused by autoantibody production resulting from excessive proliferation of B cells.

TOLERIZING IMMUNE MODIFYING NANOPARTICLES FOR TREATMENT OF ALPHA GAL SYNDROME

Resumen de: WO2026015713A1

The present application is directed, in general, to tolerizing immune modifying particles comprising antigens for use in treating alpha-gal syndrome, for example αGal containing proteins.

FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS COMPRISING PANCREATIC ENZYMES

Resumen de: AU2024288835A1

The present invention relates to a composition comprising a solid carrier, a lipase or a fragment thereof immobilized on the surface of the solid carrier wherein the lipase or a fragment thereof is in the open conformation, a protease or a fragment thereof immobilized on the surface of the solid carrier, an amylase or a fragment thereof immobilized on the surface of the solid carrier, an agent which interacts with the lid domain of the lipase or a fragment thereof, a protective layer to protect the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof by embedding the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group.

PEPTIDE-CONJUGATED PHAGE-MIMICKING NANOPARTICLES FOR INFLAMMATION FREE WOUND HEALING

Resumen de: AU2024282877A1

An antibacterial nanoparticle comprising an inner silica core; a gold (Au) nanosphere surrounding the inner silica core; a surface layer comprising silver (Ag) surrounding the gold nanosphere or the silver is alloyed into the gold nanosphere; and an antimicrobial peptide conjugated to the surface layer, wherein the antimicrobial peptide is selected from the group consisting of a cysteine terminated Syn71 peptide, a cysteine terminated MC1-2 peptide, and a cysteine terminated Syn20 peptide.

PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF

Resumen de: AU2024307171A1

A pharmaceutical composition containing a cationic lipid and the use thereof. Specifically, provided are a pharmaceutical composition comprising a carrier, the carrier comprising a cationic lipid, and the molar percentage of the cationic lipid to the carrier being greater than or equal to 10% and less than 50%.

IMMUNOSORBENT NANOPARTICLES AND METHODS OF USING THEREOF

Resumen de: AU2024303275A1

Disclosed herein are immunosorbent nanoparticles, devices, and methods for selective removal of a target protein such as beta-2 microglobulin (B2M) from a liquid such as blood.

NANOPARTICLE FORMULATIONS FOR TREATMENT OF INFLAMMATIONS

Resumen de: WO2026013059A1

The present invention provides lipid nanoparticles and formulations comprising cationic lipids and helper phospholipid. These lipid nanoparticles may be formulated with therapeutic agents to facilitate their intracellular delivery for both in vitro and in vivo therapeutic applications. The present invention is specifically directed to nanoparticles and formulations that can target inflamed tissues and treat inflammatory diseases.

INJECTABLE NANOPARTICLE SUSPENSION FOR VISION RECOVERY

Resumen de: WO2026013635A1

The disclosure refers to a composition comprising poly(3-hexylthiophene) nanoparticles suspended in a saline solution comprising a stabilizing agent selected from a non-ionic surfactant, a water-soluble polymer having high intrinsic viscosity and a combination thereof. The preferred water-soluble polymer is hyaluronic acid. The saline solution is an aqueous solution comprising at least sodium ions and chloride ions. The saline solution may further comprise at least one of: magnesium ions, calcium ions, potassium ions, and combination thereof. The formulation has demonstrated an improved effectiveness in restoring a visual response in the RCS rat model of blindness and is potentially effective in the treatment of human retinal dystrophies such as retinitis pigmentosa (RP) and macular degeneration (AMD).

AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: US20260015311A1

The present application relates to an amino lipid compound having the following structural formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and use thereof as a component of a lipid nanoparticle preparation for delivering a therapeutic agent. The present application further relates to a composition comprising the amino lipid compound, and particularly, to a lipid nanoparticle, and use thereof.

NOVEL IONIZABLE CATIONIC LIPIDS CONTAINING THIOETHER LINKAGE

Resumen de: WO2025109504A1

The invention relates to novel ionizable amine lipids incorporating one or more sulphur atoms in the tail section. These lipids can be used in combination with other components to form lipid nanoparticles with oligonucleotides. The invention describes the synthesis of the lipids of formula (I), formation and characterization of nanoparticles and biological experiments demonstrating that the lipid nanoparticles prepared with these novel lipids can efficiently deliver their cargo (e.g. RNA, DNA, mRNA, siRNA, miRNA, pDNA, circular DNA, dsRNA, small biologically active molecules) into the cells.

BIOSENSORS COMPRISING CHARGED BIOPOLYMERS AND USE THEREOF

Resumen de: CN120769984A

A biosensor for detecting the presence or amount of a charged analyte in a sample is provided. The biosensor may include a core component and a charged biopolymer component, the charged biopolymer component including one or more layers of a charged biopolymer. An outermost layer of the charged biopolymer component is oppositely charged relative to the charged analyte and is capable of binding to the charged analyte. The biosensor may comprise two or more alternating layers of oppositely charged biopolymers, each layer being oppositely charged relative to an adjacent layer. Also provided are devices coupled to the biosensor for quantifying a signal resulting from binding of the biosensor to the charged analyte, and methods of using the biosensor to detect the presence or amount of a charged analyte in a sample.

MUNS FUSION PROTEIN CAPABLE OF FORMING MICROSPHERES AND USES THEREOF

Resumen de: EP4678653A1

The invention relates to a fusion protein encoding a polypeptide based on the minimal region of the Orthoreovirus muNS protein capable of forming microspheres and/or nanospheres, modified to permit the addition of polypeptides at the C-terminal.

CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES

Nº publicación: EP4678164A2 14/01/2026

Solicitante:

ACUITAS THERAPEUTICS INC [CA]
Acuitas Therapeutics Inc

Resumen de: EP4678164A2

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G¹, G², L¹, L², R^1a, R^1b, R^2a, R^2b, R^3a, R^3b, R^4a, R^4b, R⁵, R⁶, R⁷, R⁸ and X are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, nanoparticles comprising the compounds and methods for their use and preparation are also provided.